Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label tremelimumab study in advanced solid tumors
NL-OMON47002Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tremelimumab and durvalumab in bladder cancer, pancreatic adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Jan 2016; status: active, not recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
bladder cancerpancreatic adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON47002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47002.